We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.85 | -5.31% | 33.00 | 32.85 | 33.80 | 34.75 | 33.00 | 34.25 | 459,882 | 14:23:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -17.42 | 101.64M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/6/2023 08:22 | Fortunately it seems people are ignoring the (obviously) tainted reviews and buying the product. We will get some sales figures soon enough :-) | broomrigg | |
13/6/2023 08:20 | .....the words of the fraudulent LBO (who wrote most of the negative reviews) | broomrigg | |
13/6/2023 08:14 | Yes and not surprising the reviews are not good considering it is a medical device gel that used the "least burdensome" approach to gaining medical device authorisation. ‘Ninety-nine percent of devices never have to provide clinical data, thanks in part to the 2002 Medical Devices User Fee Act, which requires the FDA to use the least burdensome route’ | drpmc | |
13/6/2023 08:09 | 23 reviews from 3000+ sales is hardly anything..... and several look like the same repeated negs you see on boots.com ....."waste of money" is LBO's favourite phrase. Hundreds and hundreds of upticks/down ticks. The reviews are totally tainted and bitter broke loser LBO has now run away hiding from his fraudulent activities. I think most buyers will refer to the official clinical trials and give it a try on that basis. The feedback on the Belgian website is much more in-line with clinical trials...... | broomrigg | |
13/6/2023 07:53 | Agree 3000+ sales - but have you read the reviews from customers - they are not glowing as many claim it is a 'waste of money', so not likely to be repeat customers. | rmjpb | |
13/6/2023 07:17 | 3000+ units sold on Amazon.co.uk in last month......https://w | broomrigg | |
13/6/2023 07:11 | https://www.cnn.com/ | broomrigg | |
13/6/2023 06:59 | https://www.thetimes | broomrigg | |
13/6/2023 06:57 | https://www.proactiv | broomrigg | |
12/6/2023 22:40 | I agree Alloa, but the most likely acquirer would be Reckitt to put Eroxon under its Durex brand. There would be no CMA issue because ED treatment would be a new category for Reckitt. Reckitt also has worldwide distribution so could cut marketing costs. I think if Reckitt believe in the product it will be a matter of months before they approach FUM with an offer. | kinwah | |
12/6/2023 20:42 | I think one of the overlooked keys here is the fact by exercising the warrants the company is doubling its cash pile. This takes away any vague rumours of a fund raising and allows them to push ahead full belt marketing the product. Faster acting and FDA approved, the company must be a takeover target - the majors wont just sit back and let them take market share. A market cap of £140m is nothing compared to the size (no pun intended lol) of the ED market. | alloa2003 | |
12/6/2023 17:18 | Buy the rumour sell the news. What are the chances there will be any ‘serious legal consequences’ from the FDA or anyone for today’s announcement even possibly suggesting that a De Novo Medical device authorisation can have ‘FDA approval’? | drpmc | |
12/6/2023 12:05 | i'm guessing the holding RNS will actually go up, even though they are selling (as I agree with you Suresure). But with an increase of 10 mil shares their holding % should be higher | keifer derrin | |
12/6/2023 11:13 | Lombard had previously reduced here. I would expect they are selling into this rise to pay for the warrants. Anything they sell above 40p is cream off the top right. They obviously expect this to go much further but they are probably selling sufficient here to hold it back. It will be interesting to see the holding RNS and when it comes. | suresure | |
12/6/2023 11:11 | Liberum 140p | j777j | |
12/6/2023 10:27 | We should now be moving towards 100p in due course | losses | |
12/6/2023 10:01 | For the FDA to grant approval then there must be side effects. | katsy | |
12/6/2023 09:26 | Time for the company to announce UK sales .Shame that one cannot believe the ratings on products , they should only allow reports where confirmed sales i.e.where image of receipt is enclosed . Initial sales will be vast even if there are no repeats .male population of USA =165.88 million just 1% = 1.6 million sales . This is a retail product so no comparison with agle and dnl . | haroldthegreat | |
12/6/2023 09:21 | Add POLX ! List endless | amaretto1 | |
12/6/2023 09:03 | Well done all not a holder A caution though Agle and Dnl both had fda approval And went down hill afterwards ! | s34icknote | |
12/6/2023 08:50 | Plus £4.375 million into coffers from Lombard Odier exercise | wapper | |
12/6/2023 08:21 | Anyone else going to the AGM on 22nd June ? Best wishes - Mike | spike_1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions